针对IGSF9的治疗抑制了急性髓性白血病的进展
Lijun Hui1, Jing Xiao2, Zhiling Zhao1
1Department of Biochemistry and Molecular Biology, Shandong Tumour Immunotherapy Research Innovation Team, Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medicine and Health Key Lab of Respiratory Infection and Tumor Immunity, Binzhou Medical University, Yantai, People's Republic of China.
Blood advances
|June 17, 2025
概括
干扰素玛 (IFN-γ) 在急性髓性白血病 (AML) 中诱导免疫球蛋白超级家族9号成员 (IGSF9),促进瘤脱离. 用抗体-药物联合体 (ADC) 向IGSF9显示出对AML瘤的显著疗效.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 免疫球蛋白超级家族9号成员 (IGSF9) 之前被确定为增强抗瘤T细胞活性和免疫治疗敏感性的标.
- IGSF9影响瘤进展和免疫逃避的确切机制尚不清楚.
- 急性髓性白血病 (AML) 在治疗方面存在挑战,需要新的治疗点.
研究的目的:
- 阐明IGSF9监管的机制及其在AML中的作用.
- 研究结合抗IGSF9疗法与抗PD-1免疫疗法的协同作用潜力.
- 开发和评估一种针对IGSF9的新型抗体-药物联合体 (ADC),用于AML治疗.
主要方法:
- 在AML细胞中研究了因子干扰素玛 (IFN-γ) 诱导IGSF9表达的过程.
- 利用向JAK1的小干扰RNA和一个STAT1抑制剂来阻止IFN-γ信号通路.
- 开发和表征了一种抗IGSF9抗体-药物合物 (抗IGSF9-链接剂-DXd),并评估了其在体外和体内疗效.
主要成果:
- IFN-γ通过JAK1/STAT1通路诱导IGSF9在AML中的表达,类似于PD-L1调节.
- IGSF9促进瘤逃逸,并调解AML细胞的外骨内透.
- 开发的抗IGSF9-链接剂-DXd ADC表现出高纯度,特异性,强大的瘤细胞杀伤,旁观者效应和显著的体内抗瘤活性.
结论:
- IGSF9是一种瘤特异性免疫检查点分子,由AML中的IFN-γ诱导,有助于免疫逃避和疾病进展.
- 针对IGSF9,特别是新型ADC,代表了AML的一个有希望的治疗策略.
- 这些发现支持IGSF9作为AML新型治疗点的潜力,为组合疗法和向治疗提供了新的途径.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K